Every prescribing information document for GLP-1 receptor agonist (GLP-1 RA) medications — including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — carries a black box warning, the FDA’s most prominent safety alert, regarding the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). For many patients and even some clinicians, this warning generates significant anxiety. Understanding exactly what the evidence shows, what it doesn’t show, and who is genuinely at risk is essential for informed decision-making about GLP-1 RA therapy.
What the Black Box Warning Actually States
The FDA black box warning for GLP-1 RAs states that these medications cause dose-dependent and duration-dependent thyroid C-cell tumors (including adenomas and carcinomas) in rodents at clinically relevant exposures. It further states that it is unknown whether these medications cause thyroid C-cell tumors in humans. Based on this uncertainty, GLP-1 RAs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients are also advised to inform their clinician if they develop a neck mass, difficulty swallowing, hoarseness, or shortness of breath.
The Rodent Data: What Was Found and Why It Matters
In preclinical carcinogenicity studies required by the FDA before drug approval, rats and mice given GLP-1 RAs at doses producing exposures many times higher than those in clinical use developed C-cell hyperplasia and C-cell tumors of the thyroid in a dose- and duration-dependent manner. Thyroid C-cells (parafollicular cells) produce calcitonin — a hormone involved in calcium metabolism. GLP-1 receptors are expressed on C-cells in rodents at significantly higher density than in humans. In rodents, GLP-1 RA stimulation of C-cell receptors leads to calcitonin secretion and, with sustained stimulation, C-cell proliferation and eventual neoplasia.
Why the Rodent Risk Does Not Straightforwardly Apply to Humans
There are several important biological differences between rodent and human thyroid C-cells:
- GLP-1 receptor expression: Rodent thyroid C-cells express high levels of GLP-1 receptors. Human thyroid C-cells express very low or undetectable levels of GLP-1 receptors in most studies. This fundamental difference dramatically reduces the biological plausibility of the same mechanism causing C-cell stimulation in humans.
- Rodent C-cell biology: Rats are known to develop spontaneous C-cell tumors at high rates with age, making them a less predictive model for human thyroid cancer.
- Calcitonin levels in clinical trials: Although calcitonin rose marginally in some GLP-1 RA clinical trials, the increases were small and values remained within the normal range for the vast majority of patients.
💡 💡 Clinical Pearl
A comprehensive review by Anastasiou et al. (2022) examined the available human epidemiological, clinical, and molecular evidence regarding GLP-1 RAs and thyroid cancer. The authors concluded that while rodent data mandated regulatory caution, current human evidence does not confirm an elevated risk of medullary thyroid carcinoma or other thyroid cancers in patients using GLP-1 RAs at clinical doses. Large observational studies involving hundreds of thousands of patient-years of GLP-1 RA exposure have not demonstrated a statistically significant increase in MTC rates compared to other antidiabetic medications. The FDA black box warning reflects appropriate regulatory precaution rather than confirmed human risk.
Human Epidemiological Evidence
Several large real-world pharmacoepidemiological studies have examined thyroid cancer risk in GLP-1 RA users. Multiple large cohort studies have found no significant increase in MTC risk, which is the specific cancer type of biological concern from the C-cell mechanism. A 2023 study published in The BMJ involving over 1 million patients found a small but statistically significant increase in thyroid cancer risk (primarily papillary thyroid cancer, not MTC) with an absolute risk difference of approximately 1 additional case per 1,000 patients over 15 years — described as small. MTC remains an extremely rare cancer overall (approximately 1,000–1,500 new cases per year in the United States), making it difficult to detect a drug-related signal even in large studies.
Absolute Contraindications: Who Should Not Use GLP-1 RAs
Regardless of the remaining scientific uncertainty, the following patient groups should not use GLP-1 RA medications:
- Personal history of medullary thyroid carcinoma (MTC)
- Family history of MTC — first-degree relatives with MTC
- Multiple Endocrine Neoplasia type 2 (MEN 2) — including MEN 2A and MEN 2B, which predispose to MTC through RET proto-oncogene mutations
Monitoring and When to Seek Evaluation
Routine baseline thyroid ultrasound or serum calcitonin measurement is not universally recommended for all patients starting GLP-1 RA therapy. However, seek medical evaluation during GLP-1 RA therapy if you notice: a new lump or swelling in the neck (thyroid nodule), persistent hoarseness or voice changes, difficulty swallowing (dysphagia), persistent neck pain, or shortness of breath without cardiac or pulmonary cause.
For broader GLP-1 RA safety information, see Pancreatitis Risk with GLP-1 RA and Gallstones and Gallbladder Disease.
💡 Frequently Asked Questions (FAQ)
Q1: I have a family history of thyroid nodules (not MTC). Can I still take semaglutide or tirzepatide?
A1: A family history of benign thyroid nodules or common thyroid cancers (such as papillary or follicular thyroid cancer) is not the same as a family history of MTC and does not constitute a contraindication to GLP-1 RA therapy. The black box warning specifically relates to medullary thyroid carcinoma and MEN 2. Discuss your specific family history with your clinician, who can assess your individual risk.
Q2: Should I have my thyroid checked before starting a GLP-1 RA medication?
A2: There is no universal guideline recommending routine thyroid testing before starting GLP-1 RA therapy for the general population. However, patients with thyroid nodules, elevated calcitonin, family history of MTC or MEN 2, or current thyroid symptoms should have their thyroid evaluated before starting therapy.
Q3: Is the thyroid cancer risk higher with one GLP-1 RA compared to another?
A3: The black box warning and underlying C-cell tumor findings apply to the entire GLP-1 RA drug class. There is no current evidence indicating that any one specific agent (semaglutide vs. liraglutide vs. tirzepatide) carries a meaningfully higher thyroid cancer risk than another at approved clinical doses.
📚 References & Sources
- Anastasiou, I. A., et al. (2022). Thyroid and GLP-1 receptor agonists: What do we know so far? International Journal of Molecular Sciences, 23(2), 644.
- FDA. (2023). Zepbound (tirzepatide) Prescribing Information — Warnings and Precautions (Black Box Warning). U.S. Food and Drug Administration.
- Husain, M., et al. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 381(9), 841–851.